FluoGuide A/S’s directed share issue registered at the Danish Business Authority

Report this content

FluoGuide A/S (“FluoGuide” or “Company”) hereby announces that the directed share issue has been formally registered at the Danish Business Authority (Danish: “Erhvervsstyrelsen”). As previously communicated, A/S Arbejdernes Landsbank and Linc AB participated with others in the directed share issue of approx. DKK 11.6 million (before issue costs of approx. DKK 0.5 million). 

The Company’s share capital has, in connection with the registration of the directed share issue, increased to DKK 945,526.80 and the total amount of registered shares is now 9,455,268.

Please visit the Company’s home page (www.fluoguide.com) for more detailed information. 

For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66


About FluoGuide 
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.

About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.